Theriva Positive Review in Phase 1b/2a Trial for Allogeneic Hematopoietic Cell Transplant

 

DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3

https://www.globenewswire.com/news-release/2024/10/03/2957647/0/en/Theriva-Biologics-Announces-Positive-Outcome-of-Data-and-Safety-Monitoring-Committee-DSMC-Review-in-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-Cel.html